Increase dermal absorption
Lipophilic and permeability-oriented strategies can be investigated for local delivery.
ExplorePrecision chemistry
ChronoSense® PMF Prodrug Platform
A modular chemistry framework is being developed to transform a nobiletin-derived core into tunable prodrug candidates.
Why it matters
Precision delivery of chronobiotics to the right place, at the right time.
A modular chemistry framework is being developed to transform a nobiletin-derived core into tunable prodrug candidates.
The platform is developmental. It is not an approved medicine, and candidate-specific pharmacology, safety and clinical work remain essential.
- Scientific rationale is distinguished from demonstrated outcomes.
- Capabilities are mapped to application, format and regulatory context.
- Confidential depth is available through qualified access rather than exposed publicly.
Designed as a platform
What makes this approach different
ChronoSense® connects the biological hypothesis to delivery, evidence, data and a controlled route to market.
Enhance oral absorption
Solubility, permeability and transporter behavior can be optimized candidate by candidate.
ExploreExtend half-life
Steric, metabolic and clearance properties can be tuned within a defined development program.
ExploreTarget tissues
Linkers and moieties can be explored for local or pathway-associated activation.
ExploreImprove stability
Protection from chemical or enzymatic degradation can be investigated.
ExploreBuild a candidate library
A modular moiety framework enables multiple candidate hypotheses from one core.
ExploreA disciplined pathway
From insight to accountable action
The platform is designed to move through explicit stages, with evidence and access appropriate to each one.
1
Select candidate objective
Define tissue, route, exposure, release trigger and therapeutic hypothesis.
2
Design and synthesize
Attach candidate moieties through cleavable or purpose-designed linkers.
3
Characterize
Assess identity, purity, stability, conversion, PK and target engagement.
4
Advance under a pharmaceutical plan
Generate candidate-specific safety, CMC, regulatory and clinical evidence.
Next step
Evaluate the pharmaceutical opportunity.
Qualified organizations can request a confidential discussion and staged data-room access.